Article - 13/05/2008 A new method unmasks noroviruses on food Noroviruses often might be the causative agents of Nausea vomiting diarrhoea fever. The Chemical and Veterinary Investigation Office in Stuttgart has now developed a method that enables the detection of these viruses on food. https://www.gesundheitsindustrie-bw.de/en/article/news/a-new-method-unmasks-noroviruses-on-food
Article - 13/05/2008 The bachelor's degree as seen by companies: jump start or pole position? The number of bachelors degree graduates in Germany is still low and companies do not yet have much experience of the new degrees. However one thing has already become clear A bachelors degree is not sufficient for all professional fields. Those hoping for a future in research must continue their university education beyond the initial six semesters.https://www.gesundheitsindustrie-bw.de/en/article/news/the-bachelor-s-degree-as-seen-by-companies-jump-start-or-pole-position
Article - 11/05/2008 Market report on antioxidants published In an independent market study by Ceresana Research the latest data facts and trends of the antioxidant market are analysed and presented. Data concerning the antioxidant market are subdivided by region based on value and quantity.https://www.gesundheitsindustrie-bw.de/en/article/press-release/market-report-on-antioxidants-published
Press release - 07/05/2008 Confidence with restrictions In their 9th German Biotechnology Report the industry experts from Ernst Young paint an essentially confident picture of the German biotech industry. However despite the general optimism the picture has a few negative points no company will go public in 2008.https://www.gesundheitsindustrie-bw.de/en/article/press-release/confidence-with-restrictions
Article - 06/05/2008 Vetter clients can concentrate fully on their core business The Ravensburg-based company Vetter Pharma-Fertigung GmbH & Co. KG is one of the leaders in biopharmaceutical contract manufacturing. We spoke with Max Horn, who has been with the company since 1981 and was appointed Managing Director in 2002.https://www.gesundheitsindustrie-bw.de/en/article/news/vetter-clients-can-concentrate-fully-on-their-core-business
Article - 04/05/2008 Better qualifications pay off At the beginning of October 2008 the MBA course on Medical Devices and Healthcare Management will commence at the INTERNATIONAL BUSINESS SCHOOL TUTTLINGEN IBST. This masters course an extra-occupational two-year distance-learning course with attendance phases.https://www.gesundheitsindustrie-bw.de/en/article/news/better-qualifications-pay-off
Article - 03/05/2008 Immatics started second proof-of-concept study Immatics biotechnologies GmbH announced the start of a Phase III trial of its IMA910 cancer vaccine in patients with advanced colorectal cancer. The study will enroll about 70 patients in 8 European countries. The vaccine is developed to slow or halt tumor progression.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-started-second-proof-of-concept-study
Press release - 03/05/2008 New course in biostatistics From the winter term 20082009 Ulm University will offer a new bachelor course in mathematical biometry. The course which is unique in Germany provides basic knowledge in applied mathematics computer science and the life sciences.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-course-in-biostatistics
Article - 01/05/2008 Peter Öhlschläger - New strategies for the treatment of cancer Professor Peter Öhlschläger established his major scientific interests very early on. During his degree thesis at the German Cancer Research Centre DKFZ in Heidelberg the immunologist succeeded in combining his two major interests namely virology and cancer. Öhlschläger is now junior professor at the University of Constance and mainly deals with the development of therapeutic cancer vaccines. https://www.gesundheitsindustrie-bw.de/en/article/news/peter-hlschlaeger-new-strategies-for-the-treatment-of-cancer
Press release - 28/04/2008 Rentschler: experts in contract manufacturing The company Rentschler from Laupheim in the south of Germany is nowadays one of the biggest biopharmaceutical contract manufacturers in Europe. This has not always been the case. A look at the companys history shows why the company which is nowadays run by the third family generation has become what it is today.https://www.gesundheitsindustrie-bw.de/en/article/press-release/rentschler-experts-in-contract-manufacturing
Press release - 21/04/2008 "Teaching does not come off badly" Since autumn 2007 Constance has been one of Germanys Elite Universities. UNI-ZEITUNG spoke with Prof. Dr. Andreas Marx spokesperson for the Department of Chemistry and head of the winning Chemical Biology graduate school about the practical consequences.https://www.gesundheitsindustrie-bw.de/en/article/press-release/teaching-does-not-come-off-badly
Article - 21/04/2008 Human blood system in mice Scientists from Mannheim Heidelberg an Freiburg working together in the cooperative research area Vascular Biology have developed a method that can be used to create a human vascular system in mice which stays functional even after several months.https://www.gesundheitsindustrie-bw.de/en/article/news/human-blood-system-in-mice
Article - 21/04/2008 Kilian Hennes - unusual ideas and a pragmatic approach People with know-how must bear responsibility said the microbiologist Dr. Kilian Hennes who lectures bioprocess engineering at Constance University of Applied Sciences HTWG. Teaching is one of the major challenges for the experienced scientist and practitioner in particular because his discipline is seen as somewhat exotic by future process engineers and requires a different way of looking at things. But this is what makes his job truly…https://www.gesundheitsindustrie-bw.de/en/article/news/kilian-hennes-unusual-ideas-and-a-pragmatic-approach
Press release - 20/04/2008 New healthcare training and education options Baden-Württemberg universities have adapted their healthcare training and education to different requirements and a number of different specialised courses are on offer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-healthcare-training-and-education-options
Article - 16/04/2008 Roland Schuele - "Research cannot be predicted" Professor Roland Schuele from the University Womens Hospital in Freiburg originally studied biochemistry. Nowadays Schuele is researching the development of prostate cancer. During his scientific career he has learnt that research cannot be steered in a particular direction. It develops and we follow it said Schuele who has been able to gain astonishing insights into the molecular processes in tumour cells.https://www.gesundheitsindustrie-bw.de/en/article/news/roland-schuele-research-cannot-be-predicted
Press release - 16/04/2008 Effective Cancer Immune Therapy Through Order in the Blood Vessels Researchers at the German Cancer Research Center have discovered a key molecule that is responsible for the immature structure of blood vessels in malignant tumors. If this molecule is switched off in mice vessels normalize so that immune cells are better able to get to the tumor tissue.https://www.gesundheitsindustrie-bw.de/en/article/press-release/effective-cancer-immune-therapy-through-order-in-the-blood-vessels
Press release - 08/04/2008 Boehringer Ingelheim continues to grow Boehringer Ingelheim enjoyed continued success in 2007 and its growth is outpacing the pharmaceuticals market for the eighth year in a row. The companys turnover rose by 8.8 in local currency to almost EUR 11 billion.https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-continues-to-grow
Article - 05/04/2008 Successful cooperation between science and industry (II) In the second article in the series on the platforms successful cooperations BioValley presents an encouraging approach for improving the quality of life of severely ill cancer patients and the successful establishment of an industrial biochip platform. https://www.gesundheitsindustrie-bw.de/en/article/news/successful-cooperation-between-science-and-industry-ii
Article - 31/03/2008 "Nanomedicine will be able to combat incurable diseases" The first European Conference for Clinical Nanomedicine is to be held soon in Basel. BIOPRO has therefore discussed this promising area of application with Beat Löffler and Dr. Patrick Hunziker the founders of the European Foundation for Clinical Nanomedicine.https://www.gesundheitsindustrie-bw.de/en/article/news/nanomedicine-will-be-able-to-combat-incurable-diseases
Article - 29/03/2008 Doctor’s rounds with virtual patients The medical online learning programme by the Tübingen-based E-learning publisher INMEDEA GmbH simulates procedures and situations in different departments of a hospital with their respective typical patient groups. https://www.gesundheitsindustrie-bw.de/en/article/news/doctor-s-rounds-with-virtual-patients
Article - 29/03/2008 Freiburg researchers discover new effect of insulin Working with colleagues from the Harvard Medical School in Boston USA researchers from Freiburg University have discovered a previously unknown role of insulin in ageing and lifespan. Insulin inhibits a master stress regulator protein known as SKN-1.https://www.gesundheitsindustrie-bw.de/en/article/press-release/freiburg-researchers-discover-new-effect-of-insulin
Article - 29/03/2008 Artificial micro RNAs in plant breeding Scientists from the Max Planck Institute for Developmental Biology in Tübingen and their colleagues from the International Rice Research Institute in the Philippines succeeded in accelerating rice plant breeding by using artificial small RNA molecules.https://www.gesundheitsindustrie-bw.de/en/article/press-release/artificial-micro-rnas-in-plant-breeding
Article - 20/03/2008 The effect of migration from Africa on genetic diversity in Europe The paper by Lohmueller et al. 2008 shows that there is proportionally more deleterious genetic variation in European than in African populations. This revelation enables conclusions to be made on the group that emigrated from Africa several thousand years ago.https://www.gesundheitsindustrie-bw.de/en/article/news/the-effect-of-migration-from-africa-on-genetic-diversity-in-europe
Article - 16/03/2008 New indication for lead compound of Apogenix Isolated tumour cells use to invade healthy brain tissue during the development and growth of glioblastoma multiforme GBM. This mechanism involves the CD95CD95L death system. These results supports the therapeutic potential of Apogenix APG101 for the treatment of glioblastomas.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-indication-for-lead-compound-of-apogenix
Article - 14/03/2008 Elisa Izaurralde, a prominent RNA scientist, receives Leibniz Prize The directors of the Tübingen Max Planck Institute MPI for Developmental Biology are pleased to have a Leibniz prizewinner in their ranks for the second year running. Dr. Elisa Izaurralde and her colleague Dr. Elena Conti have both been awarded the 2008 prize for their outstanding work in the field of RNA research. https://www.gesundheitsindustrie-bw.de/en/article/news/elisa-izaurralde-a-prominent-rna-scientist-receives-leibniz-prize